Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Author Correction: Mitochondrial fission links ECM mechanotransduction to metabolic redox homeostasis and metastatic chemotherapy resistance.

Nature cell biology·2026

Same author

Ill Fate of Rectal Mucinous Adenocarcinoma: A Defect in Immunosurveillance or a Mucin Coating Effect?-The IMMUNOREACT 20 Study.

Cancers·2026

Same author

Assessment of Vedolizumab and UC-MSC interaction and therapeutic potential in acute graft-versus-host-disease.

Frontiers in cell and developmental biology·2026

Same author

Manufacturing 3D aortic root models for in vitro assessment of calcific aortic valve stenosis.

Annals of biomedical engineering·2026

Same author

Gut microbiota-associated predictors as biomarkers of neoadjuvant treatment response in rectal cancer-a systematic review.

British journal of cancer·2026

Same author

Targeting peptidyl-arginine deiminase 4 suppresses SARS-CoV-2 replication and modulates the inflammatory response.

iScience·2026

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Immunotherapy for EBV-associated malignancies.

Anna Merlo¹, Riccardo Turrini¹, Riccardo Dolcetti²

¹Department of Oncology and Surgical Sciences, University of Padova, Via Gattamelata, 64, 35128, Padua, Italy.

International Journal of Hematology

|February 22, 2011

Summary

Virus-specific cytotoxic T lymphocytes (CTL) offer a safe and effective cell therapy for Epstein-Barr virus (EBV)-related diseases. This approach has shown success in patients resistant to conventional treatments, with ongoing advancements targeting broader applications.

More Related Videos

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Published on: September 7, 2022

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Related Experiment Videos

Last Updated: Jun 4, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Published on: September 7, 2022

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Area of Science:

Immunology
Oncology
Cell Therapy

Background:

Epstein-Barr virus (EBV) infections can lead to severe conditions like post-transplant lymphoproliferative disease (PTLD), Hodgkin's lymphoma, nasopharyngeal carcinoma, and chronic active infection.
Conventional treatments for these EBV-related diseases have limitations, particularly in patients refractory to standard therapies.

Purpose of the Study:

To review the clinical outcomes of adoptive cell therapy using Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTL).
To explore future directions and potential advancements in EBV-specific CTL therapy based on current clinical trials.

Main Methods:

Review of clinical data from over 250 patients treated with EBV-specific CTL since 1995.
Analysis of ongoing clinical trials investigating modified CTL generation protocols and chimeric antigen receptor (CAR) T-cell therapies.

Main Results:

EBV-specific CTL therapy has demonstrated safety and efficacy in treating various EBV-related diseases, including PTLD in transplant recipients.
Complete remissions have been observed in patients who did not respond to prior standard treatments.
The approach has been successfully extended to Hodgkin's lymphoma, nasopharyngeal carcinoma, and chronic active EBV infection.

Conclusions:

Adoptive cell therapy with EBV-specific CTL represents a successful and evolving treatment modality for EBV-associated malignancies and infections.
Ongoing research, including CAR T-cell modifications, is expanding the potential of CTL therapy to target other viral infections and non-EBV related cancers.